Welcome to our dedicated page for Inmune Bio news (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on Inmune Bio stock.
INmune Bio Inc. develops clinical-stage immunology and biotechnology treatments designed to target the innate immune system in disease. Company news commonly centers on three platforms: CORDStrom, a pooled allogeneic human umbilical cord-derived mesenchymal stromal/stem cell platform; XPro, a dominant-negative TNF platform intended to selectively neutralize soluble TNF; and INKmune, a cell-based medicine designed to prime natural killer cells against residual cancer.
Recurring updates include clinical and preclinical data, regulatory pathway discussions, manufacturing and collaboration agreements, conference presentations, shareholder communications, and quarterly or annual financial results. Coverage also reflects program areas such as recessive dystrophic epidermolysis bullosa, early Alzheimer’s disease, neuroinflammation, inflammatory disease and oncology.
INmune Bio (NASDAQ: INMB) will report third-quarter 2025 financial results and provide a corporate update on Thursday, October 30, 2025. Management will host a conference call and live audio webcast at 4:30 PM Eastern Time to discuss results for the quarter ended September 30, 2025.
Dial-in details: domestic 1-800-225-9448, international 1-203-518-9708, Conference ID: INMUNE. The live webcast is available at the company webcast link. A transcript will be posted ~24 hours after the call. A replay is available through November 13, 2025 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN 11159914.
INmune Bio (NASDAQ: INMB) announced that CEO David Moss will participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit on October 22, 2025 in New York City.
The panel is moderated by Jason McCarthy, Ph.D. and Mr. Moss will discuss INmune Bio’s CORDStrom™ advanced cell platform for treating Recessive Dystrophic Epidermolysis Bullosa (RDEB). Mr. Moss will be available for one-on-one meetings during the conference. Event dates: Oct 22–23, 2025; panel time: Oct 22, 8:30am ET. Registration information is provided on the event page.
INmune Bio (NASDAQ: INMB) has submitted results from its Phase 2 MINDFuL trial of XPro™ in Alzheimer's disease to npj Dementia journal. While the trial did not meet its primary endpoint in the overall population, it showed promising results in a specific subgroup of patients with both amyloid pathology and high inflammatory burden (ADi population).
Key findings in the ADi population demonstrated positive trends across cognitive, neuropsychiatric, and biological endpoints. Notably, XPro™ showed a complete absence of amyloid-related imaging abnormalities (ARIA), a common side effect in other Alzheimer's treatments, even in high-risk patients including APOE4 carriers. The company expects FDA regulatory feedback in Q1 2026.
INmune Bio (NASDAQ: INMB) has successfully completed its first commercial pilot-scale manufacturing run of CORDStrom™, a cell therapy treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB), at the Cell and Gene Therapy Catapult facility in the UK.
The milestone keeps the company on track for filing a Marketing Authorization Application (MAA) in the UK during H1 2026, followed by a Biologics License Application (BLA) in the US. CORDStrom™, which showed promising results in Phase 2 trials, is an off-the-shelf, allogeneic therapy derived from umbilical cord tissue mesenchymal stromal cells.
The successful manufacturing run demonstrates the scalability and consistency of CORDStrom™ production using a proprietary GMP-compliant process, marking a crucial step toward commercialization for treating RDEB patients.
INmune Bio (NASDAQ: INMB) reported Q2 2025 financial results and announced significant management changes. The company's MINDFuL phase 2 trial for Alzheimer's missed its primary cognitive endpoints in the overall population but showed positive trends in a pre-defined subset of patients with inflammation biomarkers. The company reported a net loss of $24.5 million for Q2 2025, compared to $9.7 million in Q2 2024.
Key developments include CEO RJ Tesi's retirement, with David Moss appointed as President & CEO, Cory Ellspermann as Interim CFO, and Kelly Ganjei as Board Chairman. The company successfully closed a $19 million registered direct offering and ended the quarter with $33.4 million in cash. INmune Bio plans to file MAA and BLA applications for CORDStrom™ in RDEB by mid-2026.
INmune Bio (NASDAQ: INMB) announced the successful completion of its Phase I/II CaRe PC trial for INKmune™ in metastatic castration-resistant prostate cancer (mCRPC). The trial met both primary and secondary endpoints, with the treatment demonstrating excellent safety across all three dose levels.
Key findings include successful NK cell activation in over 50% of patients with advanced disease, with some patients showing tumor size reduction or complete disappearance. Following these positive results, the company plans to advance to a randomized Phase 2b trial focusing on patients with less severe disease to better evaluate the drug's clinical benefits.
INmune Bio (NASDAQ: INMB), a clinical-stage inflammation and immunology company, has scheduled its Q2 2025 financial results conference call and webcast for Thursday, August 7th, 2025, at 4:30 PM EDT.
The company will discuss its quarterly results for the period ending June 30, 2025, and provide a corporate update. Investors can access the call via phone using the toll-free number 1-800-225-9448 (US) or +1-203-518-9783 (international) with Conference ID: INMUNE. A live audio webcast will be available, and a transcript will be provided approximately 24 hours after the call.
INmune Bio (NASDAQ: INMB) announced plans to release a video detailing additional findings from their Phase 2 MINDFuL trial of XPro™, their selective soluble TNF inhibitor for Alzheimer's disease. The video will follow their presentation at the Alzheimer's Association International Conference (AAIC) in Toronto.
The trial demonstrated that XPro™ showed consistent benefits after 6 months in patients with amyloid-beta pathology and specific inflammatory biomarkers. Dr. Sharon Cohen will present the data at AAIC on July 29, 2025, from 2:00 to 3:30 PM ET, with the detailed video becoming available on July 31, 2025, at 4 PM ET on INmune Bio's YouTube channel.
INmune Bio (NASDAQ: INMB) will present additional analyses from its Phase 2 MINDFuL trial of XPro™, a selective soluble TNF inhibitor for Alzheimer's disease, at the AAIC in Toronto on July 29, 2025.
The trial enrolled 208 participants with early-stage Alzheimer's, randomized 2:1 to receive XPro™ or placebo. While the primary endpoint wasn't met in the overall mITT group, the treatment showed consistent benefits after 6 months in a subgroup with confirmed amyloid-beta pathology and multiple inflammation biomarkers.
Dr. Sharon Cohen will present the findings, and INmune Bio plans to publish results by mid-August while seeking strategic partnerships for XPro™'s further development.
INmune Bio (NASDAQ: INMB), a clinical-stage inflammation and immunology company, has successfully closed its previously announced registered direct offering. The company sold 3,000,000 shares of common stock at $6.30 per share, raising approximately $19 million in gross proceeds before deducting fees and expenses.
The offering was priced at-the-market under Nasdaq rules and was conducted through A.G.P./Alliance Global Partners as the sole placement agent. The company plans to utilize the net proceeds for working capital purposes and general corporate procedures. The offering was executed under an effective shelf registration statement on Form S-3.